Key Highlights
- Dr. Satya Shreenivas, with extensive experience in interventional cardiology, joins Cardiac Dimensions as Chief Medical Officer.
- Renowned for his contributions in structural heart program and clinical trials, Dr. Shreenivas is set to enhance the EMPOWER Trial for the Carillon device.
- Carillon Mitral Contour System®, a breakthrough in treating heart failure and functional mitral regurgitation, gains momentum under Dr. Shreenivas’s leadership.
Source: Business Wire
Notable Quotes
- “We are thrilled to welcome Dr. Shreenivas to Cardiac Dimensions and expect his valuable combination of clinical and industry experience, passion for evidence generation, and innovative spirit will benefit the EMPOWER Trial studying our Carillon device as a therapy for heart failure patients with functional mitral regurgitation,” – Rick Wypych, CEO at Cardiac Dimensions
- “I’ve seen the compelling clinical evidence on Carillon therapy from Europe and look forward to helping the team expand the supportive body of evidence for this intriguing technology with the U.S. pivotal EMPOWER Trial,” – Dr. Satya Shreenivas, Chief Medical Officer at Cardiac Dimensions
SoH's Take
The appointment of Dr. Satya Shreenivas as Chief Medical Officer at Cardiac Dimensions signifies a pivotal moment in the advancement of heart failure treatments. His rich background in both clinical practice and commercial aspects of cardiology, particularly in structural heart interventions, brings a unique depth to the company’s innovative efforts. This move is especially crucial for the EMPOWER Trial, which is evaluating the Carillon Mitral Contour System’s potential in addressing heart failure with functional mitral regurgitation, a condition significantly impacting patient quality of life.
Dr. Shreenivas’s track record in leading high-profile clinical trials and his innovative approach to heart failure therapy align perfectly with Cardiac Dimensions’ mission to revolutionize minimally invasive heart treatments. The Carillon system, already showing promising results in Europe, stands to benefit greatly from his expertise and leadership. As the medical community eagerly watches the developments of the EMPOWER Trial under his guidance, this appointment marks a hopeful step towards offering heart failure patients a more effective and less invasive treatment option.
